Search company, investor...

Falcon Genomics

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$150K | 15 yrs ago

About Falcon Genomics

Falcon Genomics, Inc. is focused on functional genomics as a tool for cancer diagnostics and therapeutics.

Headquarters Location

3500 Fifth Avenue Suite 203B

Pittsburgh, Pennsylvania, 15213,

United States


Missing: Falcon Genomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Falcon Genomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Falcon Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Falcon Genomics is included in 2 Expert Collections, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Falcon Genomics Patents

Falcon Genomics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Molecular biology, Drug discovery, Oncology, Cancer treatments


Application Date


Grant Date



Related Topics

Transcription factors, Molecular biology, Drug discovery, Oncology, Cancer treatments



Latest Falcon Genomics News

Pennsylvania Biotech Falcon Genomics Files for Bankruptcy

Sep 7, 2016

   View More Jobs A Hampton biotech company has filed for financial reorganization under Chapter 11 of the U.S. Bankruptcy Code after struggling to raise investment capital. Falcon Genomics Inc. had been trying to raise $5 million to $10 million to expand the use of genetic testing in prescription medications, president Rula Abbud-Antaki said in a February Pittsburgh Post-Gazette interview. The company was founded in 2004 and offers a variety of genomic tests to predict the effectiveness of prescription drugs, including the antidepressant fluoxetine and anti-blood clotting medicine clopidogrel.

Falcon Genomics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Falcon Genomics Rank

Falcon Genomics Frequently Asked Questions (FAQ)

  • When was Falcon Genomics founded?

    Falcon Genomics was founded in 2004.

  • Where is Falcon Genomics's headquarters?

    Falcon Genomics's headquarters is located at 3500 Fifth Avenue, Pittsburgh.

  • What is Falcon Genomics's latest funding round?

    Falcon Genomics's latest funding round is Unattributed VC.

  • How much did Falcon Genomics raise?

    Falcon Genomics raised a total of $150K.

  • Who are the investors of Falcon Genomics?

    Investors of Falcon Genomics include Pittsburgh Life Sciences Greenhouse.

  • Who are Falcon Genomics's competitors?

    Competitors of Falcon Genomics include United Biomedical, Igenica Biotherapeutics, Veracyte, Celera Genomics, Sopherion and 7 more.

Compare Falcon Genomics to Competitors


Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA


Sopherion is a therapeutics platform company initially focused on cancer.


Neomics is a drug discovery and diagnostics company with a unique cancer target and biomarker discovery platform. In particular, Neomics is focused on novel targets and biomarkers relevant to aminoacyl RNA synthetases (ARS). They have preclinical and clinical validation of their targets and biomarkers.

Pro-Cure Therapeutics

Prostate Cancer - Pro-Cure Therapeutics - Enabling the development of a cure for prostate cancer based on stem cells

Immunomic Therapeutics Logo
Immunomic Therapeutics

Immunomic Therapeutics operates as a development-stage biotechnology company focusing on the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. The company develops lysosomal-associated membrane protein-based vaccines for the treatment of allergies and other human health targets. It was founded in 2005 and is based in Rockville, Maryland.


NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.